SHIDE Kotaro

写真a

Affiliation

Faculty of Medicine School of Medicine Department of Internal Medicine, Hematology, Diabetes, and Endocrinology

Title

Assistant Professor

External Link

Degree 【 display / non-display

  • 博士(医学) ( 2008.3   九州大学 )

Research Areas 【 display / non-display

  • Life Science / Hematology and medical oncology

Education 【 display / non-display

  • Kyushu University   Graduate School, Division of Medical Sciences

    - 2008.3

      More details

    Country:Japan

  • Kyushu University   Faculty of Medicine   Department of Medicine

    - 2001.3

      More details

    Country:Japan

 

Papers 【 display / non-display

  • Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis Reviewed International journal

    Shide K., Takenaka K., Kitanaka A., Numata A., Kameda T., Yamauchi T., Inagaki A., Mizuno S., Takami A., Ito S., Hagihara M., Usuki K., Maekawa T., Sunami K., Ueda Y., Tsutsui M., Ando M., Komatsu N., Ozawa K., Kurokawa M., Arai S., Mitani K., Akashi K., Shimoda K.

    Annals of Hematology   103 ( 1 )   97 - 103   2024.1

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Hematology  

    There are few prospective studies on patients with post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis (PPV-MF). Therefore, we conducted a nationwide longitudinal prospective survey to clarify the clinical characteristics of these diseases. A total of 197 PET-MF and 117 PPV-MF patients diagnosed between 2012 and 2021 were analyzed. The median age at diagnosis was 70.0 years for both diseases. The time from diagnosis of ET or PV to that of MF was 9.6 and 10.4 years, respectively, with no significant difference. Patients with PPV-MF had higher hemoglobin levels and white blood cell counts than those with PET-MF, whereas those with PET-MF had higher platelet counts than those with PPV-MF. Although splenomegaly was more frequent in patients with PPV-MF at diagnosis, there was no difference in the frequency of constitutional symptoms. Ruxolitinib was the most common treatment administered to 74.6% and 83.8% of patients with PET-MF and PPV-MF, respectively. Patients with PET-MF and PPV-MF had similar prognoses, with 3-year overall survival (OS) of 0.742 in PET-MF and 0.768 in PPV-MF patients. In both diseases, leukemic transformation was the leading cause of death, followed by infection. The 3-year OS for patients with PET/PPV-MF and primary MF diagnosed during the same period was 0.754 and 0.626, respectively, with no significant difference. This survey provides real-world clinical features and prognostic data on secondary myelofibrosis in the ruxolitinib era.

    DOI: 10.1007/s00277-023-05528-4

    Scopus

  • Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model Reviewed International journal

    Shide K., Takenaka K., Kitanaka A., Numata A., Kameda T., Yamauchi T., Inagaki A., Mizuno S., Takami A., Ito S., Hagihara M., Usuki K., Maekawa T., Sunami K., Ueda Y., Tsutsui M., Ando M., Komatsu N., Ozawa K., Kurokawa M., Arai S., Mitani K., Akashi K., Shimoda K.

    Blood Cancer Journal   13 ( 110 )   2023.7

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   Publisher:Blood Cancer Journal  

    DOI: 10.1038/s41408-023-00869-9

    Scopus

    Other Link: https://www.nature.com/articles/s41408-023-00869-9

  • SDHAF1 confers metabolic resilience to aging hematopoietic stem cells by promoting mitochondrial ATP production Reviewed International journal

    Watanuki S, Kobayashi H, Sugiura Y, Yamamoto M, Karigane D, Shiroshita K, Sorimachi Y, Morikawa T, Fujita S, Shide K, Haraguchi M, Tamaki S, Mikawa T, Kondoh H, Nakano H, Sumiyama K, Nagamatsu G, Goda N, Okamoto S, Nakamura-Ishizu A, Shimoda K, Suematsu M, Suda T, Takubo K

    Cell Stem Cell   2024.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.stem.2024.04.023.

  • CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma Reviewed International journal

    Takuro Kameda, Kotaro Shide, Ayako Kamiunten, Yasunori Kogure, Daisuke Morishita, Junji Koya, Yuki Tahira, Keiichi Akizuki, Takako Yokomizo-Nakano, Sho Kubota, Kosuke Marutsuka, Masaaki Sekine, Tomonori Hidaka, Yoko Kubuki, Yuichi Kitai, Tadashi Matsuda, Akinori Yoda, Takayuki Ohshima, Midori Sugiyama, Goro Sashida, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda

    Commun Biol   5 ( 1 )   1309   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Nature  

    DOI: 10.1038/s42003-022-04284-x.

    DOI: 10.1038/s42003-022-04284-x.

    Other Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709164/

  • C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms. Reviewed International journal

    Tabata S, Yamashita Y, Inai Y, Morita S, Kosako H, Takagi T, Shide K, Manabe S, Matsuoka TA, Shimoda K, Sonoki T, Ihara Y, Tamura S

    Scientific reports   14 ( 1 )   18858   2024.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Nature  

    DOI: 10.1038/s41598-024-69496-z

    PubMed

    Other Link: https://www.nature.com/articles/s41598-024-69496-z

display all >>

Books 【 display / non-display

  • 「原発性骨髄線維症, 真性多血症, 本態性血小板血症」最新の臨床WEB

    幣 光太郎( Role: Contributor ,  原発性骨髄線維症, 真性多血症, 本態性血小板血症)

    南江堂  2024.4 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  • 22.分子標的治療薬 19) JAK2阻害薬 新臨床腫瘍学改訂第7版

    幣 光太郎( Role: Contributor ,  22.分子標的治療薬 19) JAK2阻害薬)

    南江堂  2024.2 

     More details

    Language:Japanese Book type:Scholarly book

  • 「骨髄線維症」特発性造血障害疾患の診断の参照ガイド 令和4年度改訂版

    赤司浩一、下田和哉、桐戸敬太、竹中克斗、幣光太郎、山内拓司( Role: Contributor ,  骨髄線維症 診療の参照ガイド令和4年改訂版)

    厚生労働科学研究費補助金(難治性疾患政策研究事業) 特発性造血障害に関する調査研究班  2023.3 

     More details

    Total pages:34   Responsible for pages:231-264   Language:Japanese Book type:Scholarly book

  • 「Topics MPN分子病態研究の進歩」EBM血液疾患の治療 2023-2024

    幣 光太郎( Role: Contributor ,  Ⅲ.白血病 E.骨髄増殖性腫瘍(MPN) Topics)

    中外医学社  2022.10  ( ISBN:978-4-498-22540-4

     More details

    Total pages:572   Responsible for pages:235-236   Language:Japanese Book type:Scholarly book

  • 「多血症の鑑別診断」 ここが知りたい!血液疾患診療ハンドブック

    幣 光太郎( Role: Contributor ,  第Ⅲ章 鑑別診断 2. 多血症の鑑別診断)

    中外医学社  2022.10  ( ISBN:978-4-498-22538-1

     More details

    Total pages:304   Responsible for pages:85-93   Language:Japanese Book type:Scholarly book

display all >>

MISC 【 display / non-display

  • Development and application of mouse models of myeloproliferative neoplasms. Invited

    Kotaro Shide

    Hematology   89 ( 1 )   14 - 20   2024.7

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  • Current status of myelofibrosis in Japan Invited

    Kotaro Shide

    Hematology   88 ( 3 )   264 - 270   2024.3

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 特集〈Clinical Science〉アンメットニーズに対するJAK阻害薬の可能性骨髄増殖性腫瘍に対するJAK阻害薬の治療効果  Invited

    幣 光太郎 下田 和哉

    炎症と免疫   32 ( 2 )   29 - 32   2024.2

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:先端医学社  

  • The molecular pathogenesis of myelofibrosis and polycythemia vera, and the effect of JAK inhibitors. Invited

    Rheumatology   70 ( 6 )   608 - 614   2023.12

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • Advances in understanding the pathogenesis of myeloproliferative neoplasms. Invited

    Hematology   86 ( 5 )   745 - 749   2023.5

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

display all >>

Presentations 【 display / non-display

  • Advances in allogeneic hematopoietic stem cell transplantation and the current situation and challenges in Miyazaki Prefecture Invited

    Kotaro Shide

    The 62nd Annual Meeting of Japan Society of Clinical Oncology  2024.10.26  Japan Society of Clinical Oncology

     More details

    Event date: 2024.10.24 - 2024.10.26

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  • TYK2 Is Essential for IFNα-Induced Resolution of MPN Features in a Murine Jak2V617F PMF Model International conference

    Yuki Tahira, Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Keiichi Akizuki, Masayoshi Karasawa, Ryoma Ikeda, Kengo Matsumoto, Yoko Kubuki, and Kazuya Shimoda

    The 65th ASH Annual Meeting  (San Diego, CA)  2023.12.11  米国血液学会

     More details

    Event date: 2023.12.9 - 2023.12.12

    Language:English   Presentation type:Oral presentation (general)  

    Venue:San Diego, CA   Country:United States  

  • Significance of C-terminal amino acid sequence of CALR mutant proteins in inducing MPNs

    The 85th Annual Meeting of the Japanese Society of Hematology  (Tokyo)  2023.10.14  The Japanese Society of Hematology

     More details

    Event date: 2023.10.13 - 2023.10.15

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:Tokyo   Country:Japan  

  • COVID-19-associated thrombosis in cancer Invited

    The 45th Congress of the Japanese Society on Thrombosis and Homeostasis  2023.6.15  The Japanese Society on Thrombosis and Homeostasis

     More details

    Event date: 2023.6.15 - 2023.6.17

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

  • Role of driver mutations revealed from MPN mouse models.(Asian Session 2 : MPN study in Asia) Invited International conference

    Kotaro Shide

    The 12th JSH International Symposium 2021 in Kamaura  (Kamakura)  2021.5.14  Japanese society of Hematology

     More details

    Event date: 2021.5.14 - 2021.5.15

    Language:English   Presentation type:Oral presentation (general)  

    Venue:Kamakura   Country:Japan  

display all >>

Awards 【 display / non-display

  • 公益信託日本白血病研究基金一般研究賞

    2017.11   公益信託日本白血病研究基金   骨髄増殖性腫瘍の発症・進展における、calreticulin機能不全の分子機構解明と治療法への展開

    幣 光太郎

     More details

    Award type:Award from publisher, newspaper, foundation, etc.  Country:Japan

  • 平成25年度日本血液学会奨励賞

    2013.10   日本血液学会  

    幣 光太郎 宮崎大学 内科学講座 消化器血液学分野

     More details

    Award type:Award from Japanese society, conference, symposium, etc.  Country:Japan

Grant-in-Aid for Scientific Research 【 display / non-display

  • 炎症と血栓形成の新仮説に基づく骨髄増殖性腫瘍の病態制御

    Grant number:23K07817  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Principal investigator 

  • 腫瘍性fibrocyteの本態解明と、骨髄線維症診断・治療への展開

    Grant number:23H02938  2023.04 - 2026.03

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(B)

    下田 和哉

      More details

    Authorship:Coinvestigator(s) 

  • CALR変異幹細胞の増幅機構及び変異体の機能モチーフを標的とした骨髄線維症の制御

    Grant number:19K08819  2019.04 - 2022.03

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  • CALRが関わる造血シグナル伝達と、その破綻による骨髄増殖性腫瘍発症機序の解明

    2016.04 - 2019.03

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  • 骨髄線維症における難治性病態の分子メカニズム解明とその克服

    2014.04 - 2016.03

    科学研究費補助金  若手研究(B)

      More details

    Authorship:Principal investigator 

    骨髄線維症における難治性病態の分子メカニズム解明とその克服

display all >>